CN102258554A - New medicine for treating senile dementia - Google Patents
New medicine for treating senile dementia Download PDFInfo
- Publication number
- CN102258554A CN102258554A CN 201010185814 CN201010185814A CN102258554A CN 102258554 A CN102258554 A CN 102258554A CN 201010185814 CN201010185814 CN 201010185814 CN 201010185814 A CN201010185814 A CN 201010185814A CN 102258554 A CN102258554 A CN 102258554A
- Authority
- CN
- China
- Prior art keywords
- senile dementia
- new medicine
- new drug
- dementia
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims abstract description 6
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 claims abstract description 5
- RKFAZBXYICVSKP-UHFFFAOYSA-N beta- asarone Natural products COC1=CC(OC)=C(C=CC)C=C1OC RKFAZBXYICVSKP-UHFFFAOYSA-N 0.000 claims abstract description 5
- RKFAZBXYICVSKP-WAYWQWQTSA-N beta-asarone Chemical compound COC1=CC(OC)=C(\C=C/C)C=C1OC RKFAZBXYICVSKP-WAYWQWQTSA-N 0.000 claims abstract description 5
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims abstract description 5
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000004530 micro-emulsion Substances 0.000 claims abstract description 4
- 201000004810 Vascular dementia Diseases 0.000 claims abstract description 3
- 239000000839 emulsion Substances 0.000 claims abstract description 3
- 239000007924 injection Substances 0.000 claims abstract description 3
- 238000002347 injection Methods 0.000 claims abstract description 3
- 239000006187 pill Substances 0.000 claims abstract description 3
- 239000007787 solid Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 239000002547 new drug Substances 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 5
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 claims description 4
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 4
- 241000180649 Panax notoginseng Species 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- FACFHHMQICTXFZ-UHFFFAOYSA-N 2-(2-phenylimidazo[1,2-a]pyridin-3-yl)ethanamine Chemical compound N1=C2C=CC=CN2C(CCN)=C1C1=CC=CC=C1 FACFHHMQICTXFZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 abstract 1
- 229940067137 musk ketone Drugs 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a new medicine for treating the senile dementia. The new medicine is prepared from four active ingredients, namely musk ketone, beta-asarone, panax notoginseng saponins and icariin in a certain proportion; and the new medicine has special treatment effect on the senile dementia and the vascular dementia. The preparation formulation of the medicine can be solid preparation such as tablets, capsules, particles, pills and the like, and also can be liquid preparation such as oral liquid, emulsion, microemulsion and injection and the like.
Description
Technical field: the invention belongs to pharmaceutical sanitary field.
Background technology: alzheimer disease is human commonly encountered diseases, frequently-occurring disease, difficult disease, owing to environmental pollution, dietary structure is unreasonable and its sickness rate of multiple reason such as wound, disease is fast rise trend, has a strong impact on people's health and patient's dignity.But the treatment alzheimer disease never has ideal medicament, and the anti-treatment of alzheimer disease almost is in stage at a loss what to do.Development treatment alzheimer disease has become the urgent and great problem of medicine research and development.Along with going deep into of scientific research, people more and more clearly recognize alzheimer disease be old body particularly in the cerebral tissue multiple factor imbalance as: the blood supply in brain deficiency, big cerebral microcirculation disturbance, cerebral tissue cholinesterase activity are too high, cerebral tissue aluminum, lead, inflammatory factor level are too high, the cerebral tissue superoxide dismutase activity cross low etc. due to.The treatment alzheimer disease is not a target spot, the problem that ingredient can solve, and need take multicomponent, many target spots, multipath Comprehensive Treatment at etiology and pathogenesis.Chinese medicine has significant advantage and experience accumulation in this respect.But, the treatment alzheimer disease writes out a prescription in aspect defectives such as preparation technology, dosage form, drug loading, effective dose, compliances because need taking for a long time with traditional Chinese medicine, Chinese medicine is difficult to be not fully exerted in the curative effect aspect the treatment alzheimer disease, and the treatment advantage is not fully manifested.This research is exactly to start with from the experience prescription of the famous Traditional Chinese Medicine experts treatment of research excavation alzheimer disease, optimizes the Chinese medicine best prescription by pharmacology, pharmacodynamic study; Excellent through extracting purification, and then select " best compatibility " composition (component) and best proportion compatibility, and then " composition of medicine " of development treatment alzheimer disease.
At above problem, the novel anti senile dementia preparation that the present invention develops is fast at alzheimer disease Different types of etiopathogenises pathogenesis, determined curative effect, produce effects, lasting medicine, toxic and side effects are little, facilitate patients.
Concrete summary of the invention is as follows, and a kind of new drug for the treatment of senile dementia is characterized in that it comprises the following aspects:
(1) muscone, beta-Asarone, Radix Notoginseng total arasaponins, icariin are formed in this new drug.
(2) with the described drug ratios of claim (3) be: 0～2: 0～100: 0～300: 0～300.
(3) dosage form of this new drug is that this pharmaceutically dosage form is liquid preparations such as solid preparations such as tablet, capsule, granule, pill or oral liquid, mixture, Emulsion, microemulsion, injection.
(4) this new drug is mainly used in treatment alzheimer disease, vascular dementia and mixed type dementia.
Embodiment 1
Muscone, beta-Asarone, Radix Notoginseng total arasaponins, icariin ratio are: 1: 50: 100: 200, add suitable adjuvant, capsule.
Embodiment 2
Muscone, beta-Asarone, Radix Notoginseng total arasaponins, icariin ratio are: 1: 60: 200: 260, add suitable adjuvant, and make oral micro-emulsion.
Claims (1)
1. new drug for the treatment of senile dementia is characterized in that it comprises the following aspects:
(1) muscone, beta-Asarone, Radix Notoginseng total arasaponins, icariin are formed in this new drug.
(2) with the described drug ratios of claim (3) be: 0～2: 0～100: 0～300: 0～300.
(3) dosage form of this new drug is that this pharmaceutically dosage form is liquid preparations such as solid preparations such as tablet, capsule, granule, pill or oral liquid, mixture, Emulsion, microemulsion, injection.
(4) this new drug is mainly used in treatment alzheimer disease, vascular dementia and mixed type dementia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010185814 CN102258554A (en) | 2010-05-28 | 2010-05-28 | New medicine for treating senile dementia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010185814 CN102258554A (en) | 2010-05-28 | 2010-05-28 | New medicine for treating senile dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102258554A true CN102258554A (en) | 2011-11-30 |
Family
ID=45005520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010185814 Pending CN102258554A (en) | 2010-05-28 | 2010-05-28 | New medicine for treating senile dementia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102258554A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110638823A (en) * | 2019-10-25 | 2020-01-03 | 贵州中医药大学 | Application of icariin in preparation of medicine for treating vascular dementia |
-
2010
- 2010-05-28 CN CN 201010185814 patent/CN102258554A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 《中国优秀硕士学位论文全文数据库》 20061231 郑明 淫羊藿苷伍用三七总皂苷改善血管性痴呆大鼠空间学习记忆及抗海马凋亡机制研究 第1、36页 1 , * |
| 《中国老年学杂志》 20070630 江湧等 beta-细辛醚对痴呆小鼠学习记忆能力及SOD、GSH2Px和MDA水平的影响 第1126-1127页 第14卷, 第4期 * |
| 《江西中医学院学报》 20020430 黄丽萍等 麝香酮抗痴呆作用的药理学实验研究 第21-23页 1 第14卷, 第4期 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110638823A (en) * | 2019-10-25 | 2020-01-03 | 贵州中医药大学 | Application of icariin in preparation of medicine for treating vascular dementia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2508191A1 (en) | Combination therapy for treatment of patients with neurological disorders and cerebral infarction | |
| WO2009000145A1 (en) | Use and preparation of paeoniflorin and the composition thereof | |
| CN102283895A (en) | Preparation technology and production method of integrated novel Lingguizhugan decoction dosage form | |
| CN101843694A (en) | Chinese medicament for treating chronic hepatitis | |
| EP1952816A1 (en) | Multi-component herbal composition for the treatment of male erectile dysfunction | |
| CN102631421A (en) | Traditional Chinese medicine for treating senile dementia | |
| CN102895632A (en) | Preparation technology and production method for integrated new formulation of life-prolonging decotion | |
| CN117497202A (en) | Method for integrating PK (cardiovascular disease) by multiple ingredients of weighted integration anti-MI (MI) function traditional Chinese medicine cardiovascular prescription and application | |
| CN102283897A (en) | Preparation technology and production method of integrated novel Fangji Huangqi decoction dosage form | |
| CN102114195A (en) | Anti-drug capsule prepared from pure traditional Chinese medicines | |
| CN102258554A (en) | New medicine for treating senile dementia | |
| CN101152196A (en) | Application of Panax notoginseng saponins and its monomers in the preparation of drugs for treating depression | |
| WO2009070922A1 (en) | Pharmaceutical compositions for treating anxiety | |
| CN108926561A (en) | Application of the jateorrhizine in prevention and treatment dementia or improvement memory class product | |
| CN102166282B (en) | Anti-allergic or desensitized pharmaceutical composition | |
| CN103341117B (en) | Composition for treating hepatitis B and preparation method and usage thereof | |
| CN1083271C (en) | Drug for curing stone of urinary system | |
| CN102228521A (en) | New Chinese medicine for treating early and middle-stage diabetic nephropathy | |
| CN104606636A (en) | Traditional Chinese medicine composition for treating depression and preparation method thereof | |
| CN1250244C (en) | Composition for preventing and treating hyperlipidemia | |
| CN103736085B (en) | A kind of medicine of prevention and therapy alzheimer disease | |
| CN102847085A (en) | Preparation process and production method for Magnolia Officinalis Seven-Ingredient Decoction preparation in an integrated new dosage form | |
| US8486460B2 (en) | Herbal composition for lowering likelihood of stroke and methods for healing stroke patients | |
| CN102847092A (en) | Preparation process of integration-type novel formulation of Evodia rutaecarpa decoction and production method thereof | |
| CN101732637A (en) | Chinese medicament for treating cardiovascular and cerebrovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111130 |